USPTO Art Unit 1615 Prosecution Statistics

Art Unit Information

Art Unit: 1615
Group: 1610
Tech Center: 1600
Total Cases: 16,880
Last Active: January 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19025220GELS FOR INSULIN DELIVERYJanuary 2025April 2025Allow310NoNo
19013003PHARMACEUTICAL SOLUTION OF AMLODIPINEJanuary 2025June 2025Allow510NoNo
19005284DRUG POWDERIZATION WITHIN VIALSDecember 2024June 2025Allow610NoNo
19004850MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOFDecember 2024June 2025Allow610NoNo
19004480IMMUNOMODULATORY HYDROGEL AND PREPARATION METHOD THEREOFDecember 2024June 2025Allow610NoNo
18978361Liquid supramolecular self-recognition system of low-pH azelaic acid, and preparation method therefor and application thereofDecember 2024April 2025Allow411YesNo
18977541COMPOSITIONS AND COMPOUNDS CONTAINNG BETA-HYDROXYBUTYRATE AND ONE OR MORE AMINO ACIDSDecember 2024March 2025Allow300YesNo
18977838LEONURINE NANOCOMPOSITE HYDROGEL AND PREPARATION METHODS AND APPLICATIONS THEREOFDecember 2024April 2025Allow410NoNo
18975144MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOFDecember 2024February 2025Allow210NoNo
18953603TAMPER RESISTANT DOSAGE FORMSNovember 2024February 2025Allow310NoNo
18950649BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELSNovember 2024February 2025Allow310NoNo
18926566COENZYME Q10 COMPOSITION, AND PREPARATION METHOD AND APPLICATION THEREOF IN CARDIO-PROTECTIONOctober 2024January 2025Allow300NoNo
18921291PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINEOctober 2024March 2025Allow510YesNo
18911732MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOFOctober 2024December 2024Allow210NoNo
18897657OPHTHALMIC FORMULATIONS AND METHODS OF USESeptember 2024January 2025Allow410NoNo
18893805TREATMENT OF DIABETIC RETINOPATHY WITH OPHTHALMIC COMPOSITIONSSeptember 2024April 2025Allow610NoNo
18893796STABILIZED OPHTHALMIC DEXAMETHASONE COMPOSITIONSSeptember 2024May 2025Allow810NoNo
18893790TREATMENT OF OCULAR INFLAMMATION FOLLOWING OCULAR SURGERYSeptember 2024May 2025Allow710YesNo
18893806PH STABILIZED OPHTHALMIC DEXAMETHASONE COMPOSITIONSSeptember 2024May 2025Allow810YesNo
18893810PH STABILIZED OPHTHALMIC COMPOSITIONSSeptember 2024May 2025Allow810NoNo
18889055MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSSeptember 2024February 2025Allow500NoNo
18889023MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSSeptember 2024December 2024Allow300YesNo
18889070MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSSeptember 2024January 2025Allow400NoNo
18830440COMPOSITION AND METHOD FOR REDUCING RISK OF HYPOCALCEMIA IN PERIPARTURIENT RUMINANT ANIMALSSeptember 2024March 2025Allow620YesNo
18816200PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOFAugust 2024January 2025Allow510NoNo
18799983COMPOSITION AND METHOD FOR TREATING HEARING LOSSAugust 2024April 2025Allow811YesNo
18797696Mycophenolate Oral SuspensionAugust 2024November 2024Allow310YesNo
18797717Mycophenolate Oral SuspensionAugust 2024December 2024Allow410NoNo
18794390ADAGRASIB SOLID PHARMACEUTICAL COMPOSITIONSAugust 2024February 2025Allow620YesNo
18791632MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOFAugust 2024October 2024Allow210NoNo
18789870MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOFJuly 2024September 2024Allow210NoNo
18780575SUBCUTANEOUS INJECTION METHOD FOR PAIN TREATMENTJuly 2024October 2024Allow300YesNo
18779499PHARMACEUTICAL COMPOSITIONSJuly 2024September 2024Allow200YesNo
18777570METHODS FOR PREPARING PRODUCTS FOR TREATING SCALD INFECTION CAUSED BY PSEUDOMONAS AERUGINOSAJuly 2024January 2025Allow610YesNo
18761898MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESJuly 2024January 2025Allow710YesNo
18762128MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESJuly 2024February 2025Allow710YesNo
18760757MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJuly 2024June 2025Abandon1110NoNo
18760549COMPOSITIONS AND METHODS FOR SUNLESS TANNINGJuly 2024January 2025Allow620YesNo
18758699MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJune 2024December 2024Allow610NoNo
18758081MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJune 2024October 2024Allow410YesNo
18759320MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJune 2024February 2025Allow710YesNo
18759364MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJune 2024December 2024Allow610NoNo
18755045MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOFJune 2024August 2024Allow210NoNo
18744999Roflumilast Formulations with an Improved Pharmacokinetic ProfileJune 2024November 2024Allow510NoNo
18745572Dry Powdered Compositions and Methods and Uses ThereofJune 2024March 2025Allow900YesNo
18679670INTRANASAL ADMINISTRATION OF ESKETAMINEMay 2024April 2025Abandon1110NoNo
18670960METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORSMay 2024June 2025Allow1310NoNo
18667581TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHANMay 2024April 2025Allow1120NoNo
18666141SHELF-STABLE FORMULATIONS OF BENZOYL PEROXIDE AND METHODS OF PRODUCING SAMEMay 2024March 2025Abandon1010NoNo
18665222SELENIUM DISULFIDE COMPOSITIONS FOR USE IN TREATING MEIBOMIAN GLAND DYSFUNCTIONMay 2024June 2025Allow1430YesNo
18664846METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTIONMay 2024June 2025Abandon1320NoNo
18664248CANNABIS COMPOSITIONS, ORAL PRODUCTS, AND METHODS OF MAKING SAMEMay 2024December 2024Allow711YesNo
18664253SURGICAL REPAIR GRAFTMay 2024May 2025Allow1210YesNo
18662430METHOD OF IMPROVING FLAVOR OF A COMPOSITION OF (D)-BETA-HYDROXYBUTYRIC ACID AND (D)-1,3 BUTANEDIOL AND USE AS A NUTRITIONAL SUPPLEMENT AND THERAPEUTIC AGENTMay 2024June 2025Allow1310NoNo
18660021NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITIONMay 2024May 2025Allow1220YesNo
18655687COMPOSITIONS AND DOSAGE FORMS FOR ORAL DELIVERYMay 2024June 2025Allow1310YesNo
18653190PHARMACEUTICAL SOLUTION OF AMLODIPINEMay 2024October 2024Allow510NoNo
18652380METAL OXIDE ENCAPSULATED DRUG COMPOSITIONS AND METHODS OF PREPARING THE SAMEMay 2024June 2025Allow1410NoNo
18643422NERATINIB-CYCLODEXTRIN COMPOSITION AND METHOD FOR PREPARING SAMEApril 2024February 2025Allow1011YesNo
18643773MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSApril 2024August 2024Allow410NoNo
18703772SKIN BARRIER PROTECTIVE DELIVERY SYSTEMSApril 2024September 2024Allow410NoNo
18703841SKIN BARRIER PROTECTIVE DELIVERY SYSTEMSApril 2024August 2024Allow410YesNo
18703824APIXABAN SUSPENSION AND PREPARATION METHODApril 2024September 2024Allow510NoNo
18636861METHOD FOR TREATING BURNS WITH BRAZILIAN GREEN PROPOLISApril 2024July 2024Allow300YesNo
18633642PHARMACEUTICAL COMPOSITION FOR TREATING OR IMPROVING EDEMA AND BLOOD STASIS AFTER OPEN SURGERYApril 2024February 2025Allow1010NoNo
18700209BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATEApril 2024April 2025Allow1200YesNo
18631405TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF A COLCHICINE DERIVATIVEApril 2024March 2025Allow1120NoNo
18629986DISSOLVING MICRONEEDLE CONTAINING CANNABIDIOL SUSPENSION AND PREPARATION METHOD THEREOFApril 2024August 2024Allow410YesNo
18628237TOPICAL COMPOSITIONS COMPRISING EMULSIFIED POVIDONE IODINE SOLUTIONS AND METHODS OF PREPARATIONApril 2024June 2025Allow1410YesNo
18623901COMPOSITIONS AND FORMULATIONS FOR USE OF A PK INHIBITOR FOR THE PREVENTION, TREATMENT, AND IMPROVEMENT OF SKIN DISEASES, CONDITIONS, AND DISORDERSApril 2024December 2024Allow920YesNo
18620329IMPLANTABLE DEPOTS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTSMarch 2024February 2025Allow1110YesNo
18618702COMPOSITION AND METHOD FOR REDUCING RISK OF HYPOCALCEMIA IN PERIPARTURIENT RUMINANT ANIMALSMarch 2024August 2024Allow420YesNo
18613633Methods For Treating Pancreatic Cancer Using Combination TherapiesMarch 2024April 2025Abandon1310NoNo
18608090PYRAZOLE DERIVATIVE AND HARMFUL ORGANISM-CONTROLLING AGENTMarch 2024October 2024Allow700NoNo
18606903ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDSMarch 2024August 2024Allow510NoNo
18606925ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDSMarch 2024August 2024Allow510NoNo
18606946ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDSMarch 2024August 2024Allow510NoNo
18605258PHARMACEUTICAL COMPOSITIONS COMPRISING AKT PROTEIN KINASE INHIBITORSMarch 2024June 2025Allow1510NoNo
18598377ACID/ANIONIC ANTIMICROBIAL AND VIRUCIDAL COMPOSITIONS AND USES THEREOFMarch 2024April 2025Allow1320NoNo
18597574Roflumilast Formulations with an Improved Pharmacokinetic ProfileMarch 2024May 2024Allow200YesNo
185959853, 7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USEMarch 2024January 2025Allow1110NoNo
18591994ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANSFebruary 2024July 2024Allow510NoNo
18592160SOLID SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONSFebruary 2024March 2025Abandon1310NoNo
18588820Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseFebruary 2024August 2024Allow620YesNo
18588996Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseFebruary 2024September 2024Allow620YesNo
18588938Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseFebruary 2024August 2024Allow620YesNo
18588687Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseFebruary 2024July 2024Allow510YesNo
18588892Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseFebruary 2024August 2024Allow620YesNo
18585349Long Acting Injectable Formulation Comprising Risperidone And Biodegradable PolymersFebruary 2024April 2025Allow1320YesNo
18581968NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENTFebruary 2024July 2025Allow1621YesNo
18442802Mycophenolate Oral SuspensionFebruary 2024July 2024Allow510YesNo
18442765Mycophenolate Oral SuspensionFebruary 2024August 2024Allow610YesNo
18437420EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINEFebruary 2024September 2024Allow800NoNo
18436072PHOSPHODIESTERASE-5 INHIBITOR COMBINATIONS, METHODS OF MAKING, AND METHODS OF USE THEREOFFebruary 2024November 2024Abandon910NoNo
18434155COATED TABLETS FOR PH-DEPENDENT RELEASE OF BENZGALANTAMINEFebruary 2024September 2024Allow710YesNo
18434065SUSTAINED RELEASE MELATONIN COMPOSITIONSFebruary 2024July 2024Allow610YesNo
18425676PHARMACEUTICAL AEROSOL PRODUCT FOR ADMINISTRATION BY ORAL OR NASAL INHALATIONJanuary 2024March 2025Allow1410NoNo
18425208TUNABLE, CONTROLLED-RELEASE, URETHANE-CONTAINING ELASTOMERS AND PROCESSES OF FORMING THE SAMEJanuary 2024February 2025Abandon1301NoNo
18424936INSULIN FORMULATIONS AND METHODS OF USING SAME IN PRETERM INFANTSJanuary 2024May 2025Allow1631NoNo
18425556Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancerJanuary 2024April 2025Allow1420YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1615.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
364
Examiner Affirmed
256
(70.3%)
Examiner Reversed
108
(29.7%)
Reversal Percentile
36.1%
Lower than average

What This Means

With a 29.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
2012
Allowed After Appeal Filing
495
(24.6%)
Not Allowed After Appeal Filing
1517
(75.4%)
Filing Benefit Percentile
15.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 24.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1615 - Prosecution Statistics Summary

Executive Summary

Art Unit 1615 is part of Group 1610 in Technology Center 1600. This art unit has examined 16,880 patent applications in our dataset, with an overall allowance rate of 56.7%. Applications typically reach final disposition in approximately 31 months.

Comparative Analysis

Art Unit 1615's allowance rate of 56.7% places it in the 11% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1615 receive an average of 2.15 office actions before reaching final disposition (in the 76% percentile). The median prosecution time is 31 months (in the 35% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.